Bcl-2

Bcl-2 Suppliers list
Company Name: Shanghai Yaji Biological Technology Co., Ltd.  
Tel: 021-34661275 15301693058
Email: yajikit@163.com
Products Intro: Product Name:Bcl-2
Package:1/ RMB 1200
Company Name: Shanghai Huzhen Industrial Co., LTD  
Tel: 021-60345367 13916550749
Email: sales@shzbio.com
Products Intro: Product Name:Bcl-2
Purity:> 99% Package:50ul/RMB 1580;100ul/RMB 2680 Remarks:Apoptosis regulator Bcl 2; Apoptosis regulator Bcl2; AW986256
Company Name: Beijing Boorsen Biotechnology Co., Ltd  
Tel: 400-901-9800 18611424007
Email: cis@bioss.com.cn
Products Intro: Product Name:Mouse Anti-Bcl-2 antibody
Package:50ul;100ul
Company Name: United States Biological  
Tel: 1-800-520-3011
Email: sales@advtechind.com
Products Intro: Product Name:BCL2
Company Name: Shanghai Xuanya Biotechnology Co., Ltd.  
Tel: 021-62457717
Email: 1517347860@qq.com
Products Intro: Product Name:Bcl-2
Bcl-2 Basic information
Product Name:Bcl-2
Synonyms:Bcl-2;Recombinant Human Bcl-2 (1-218);ANTI-PHOSPHO-BCL-2(T56) antibody produced in rabbit;Apoptosis regulator Bcl-2;BCL2, GST tagged human;B-cell leukemia/lymphoma 2;Bcl-2 Active human;Anti-BCL2A1 antibody produced in rabbit
CAS:
MF:
MW:0
EINECS:
Product Categories:proteins
Mol File:Mol File
Bcl-2 Structure
Bcl-2 Chemical Properties
storage temp. -20°C
Safety Information
Hazard Codes Xn
Risk Statements 22
HS Code 3504009000
MSDS Information
Bcl-2 Usage And Synthesis
PharmacologyBCL-2 has been characterized in SCLC via immunohistochemistry, microarray detection of mRNA, genomic sequencing and proteomic profiling with levels up to 84%. In preclinical models, BCL-2 binds and sequesters BH3-only proapoptotic proteins BID or BIM and prevents them from interacting with the pore-forming effectors that lead to apoptosis and cell death. Understanding of the mechanism of BCL-2 proteins has led to two approaches to inhibiting this pathway, either by direct inhibition of BCL-2 or using BH-3 mimetics. ABT-263, a BH3 mimetic, demonstrated antitumor activity in laboratory models of SCLC but unfortunately has not led to repeated success in the clinic. Phase II trials of ABT-263 have not demonstrated success. Out of 26 patients, only 1 showed a response to treatment with ABT-263. Venetoclax, an effective BCL-2 inhibitor which has been effective clinically in treating a variety of hematologic malignancies, has also been investigated. Preclinical data appears promising as venetoclax, dosed at 100?mg/kg/qd, induced tumor regression in mouse models, and further investigation is required.
Bcl-2 Preparation Products And Raw materials
Tag:Bcl-2 Related Product Information